Examination of the long-term efficacy and safety of switching from entecavir to tenofovir alafenamide, including the anti-carcinogenic effect

Takuya Matsubara; Satoru Hagiwara; Naoshi Nishida; Naoya Omaru; Akihiro Yoshida; Tomoki Yamamoto; Yoriaki Komeda; Mamoru Takenaka; Masatoshi Kudo

doi:10.21203/rs.3.rs-5126210/v1

Back

Examination of the long-term efficacy and safety of switching from entecavir to tenofovir alafenamide, including the anti-carcinogenic effect

Preprint 2024 en

Discussion(0)

No comments yet. Be the first to comment.

Open reviews(0)

Public, signed peer feedback on this preprint.

No reviews yet.

Related publications

Article2021

Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long‐term effects from a prospective study

Satoru Hagiwara, Naoshi Nishida, Kazuomi Ueshima, Akihiro Yoshida, Yasunori Minami, Masatoshi Kudo

Article2019

Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B

Satoru Hagiwara, Naoshi Nishida, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Masahiro Takita, Yoriaki Komeda, Masatoshi Kudo

Article2025

Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B

Takuya Matsubara, Satoru Hagiwara, Naoshi Nishida, Naoya Omaru, Akihiro Yoshida, Tomoki Yamamoto, Yoriaki Komeda, Mamoru Takenaka, Masatoshi Kudo

Article2021

Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study

Fumitaka Suzuki, Yoshiyuki Suzuki, Yoshiyasu Karino, Yasuhito Tanaka, Masayuki Kurosaki, Hiroshi Yatsuhashi, Tomofumi Atarashi, Masanori Atsukawa, Tsunamasa Watanabe, Masaru Enomoto, Masatoshi Kudo, Naoto Maeda, Hiroshi Kohno, Kouji Joko, Kojiro Michitaka, Koichiro Miki, Kazuhiro Takahashi, Tatsuya Ide, Shigetoshi Fujiyama, Tomoko Kohno, Hiroshi Itoh, Sakiyo Tsukamoto,

Article2017

Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections

De Clercq Erik